6:41 AM ET
10-Q
Financial Results
Rein Therapeutics Q3 2026 Results: Net Loss of $5.54M, Loss Narrows
Rein Therapeutics reported a net loss of $17.8 million for the nine months ended September 30, 2026, compared to $17.9 million in the prior year. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $35.5 million in cash and short-term investments compared to $3.2 million at the end of 2025.
- Key figure
- Net loss $5.54M